is a biopharmaceutical company focused on improving the treatment of cardiovascular disease.
(NASDAQ ticker: AMRN)
Contact: Eric Aguiar
is a developer of next-generation medicines with improved safety and performance and a pioneer in the targeted application of deuterium chemistry to clinically validated drugs.
Contact: Pratik Shah
is developing new and more effective therapies for cancer based on its proprietary CombiPlex® technology.
Contact: Alex Zisson
is developing new approaches for hormone replacement therapy.
Contact: Alex Zisson
develops and brings to market safe, high-quality pharmaceuticals for site-specific delivery to the central nervous system to treat neurological disorders and chronic pain.
Contact: Pratik Shah
is a developer of sterile generic and specialty pharmaceutical products.
Contact: Alex Zisson
NeuroTherapeutics Pharma, Inc.
is focused on the development of novel therapeutics for the treatment of CNS disorders.
Contact: Jason Brown
is focused on the development of pharmaceutical products for gastrointestinal and liver diseases.
Contact: Pratik Shah
is a respiratory drug delivery company developing dry powder delivery systems for the treatment of asthma and COPD.
(acquired by Sandoz, a division of Novartis AG, ticker: NVS)
Contact: Eric Aguiar
Quinnova Pharmaceuticals, Inc.
is a specialty pharmaceutical company focused on the development and commercialization of prescription drug products based on innovative drug delivery platforms for the dermatology market.
(acquired by AmDerma Pharmaceuticals, LLC)
Contact: Alex Zisson
manufactures and markets Myobloc™, an FDA approved formulation of Botulinum Toxin type B, for the treatment of neurologically-induced muscle spasms.
(acquired by USWorldMeds)
Contact: James Thomas
is a specialty pharmaceutical company focused on the development and commercialization of medicines to treat CNS disorders and pain, with an initial focus on SUMAVEL™ DosePro™, a needle-free migraine treatment.
(NASDAQ ticker: ZGNX)
Contact: Alex Zisson